Avalo Therapeutics (AVTX) EBIT (2014 - 2026)
Avalo Therapeutics (AVTX) posted EBIT of -$20.9 million for Q1 2026, down 5.87% on a QoQ basis from -$19.7 million in Q4 2025, and down 42.48% year-over-year from -$36.3 million in Q1 2025.
Avalo Therapeutics (AVTX) EBIT (2014 - 2026) Analysis & Trends
Avalo Therapeutics' EBIT history runs 13 years deep, the most recent figure standing at -$20.9 million for Q1 2026.
- Quarterly EBIT fell 42.48% year-over-year to -$20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$79.2 million (down 57.01% YoY) and the FY2025 annual result came in at -$72.9 million, down 6.44% from the prior year.
- EBIT was -$20.9 million for Q1 2026 at Avalo Therapeutics, down from -$19.7 million in the prior quarter.
- Across five years, EBIT topped out at $4.1 million in Q3 2022 and bottomed at -$32.8 million in Q1 2024.
- A 5-year average of -$13.4 million and a median of -$12.9 million in 2024 frame the typical range for EBIT.
- Annual changes were most pronounced in 2022 — EBIT soared 124.87% — and 2024, when it sank 272.69%.
- Avalo Therapeutics' EBIT stood at -$8.9 million in 2022, then grew by 13.52% to -$7.7 million in 2023, then sank by 73.82% to -$13.3 million in 2024, then sank by 48.31% to -$19.7 million in 2025, then dropped by 5.87% to -$20.9 million in 2026.
- Business Quant data shows AVTX's EBIT at -$20.9 million in Q1 2026, -$19.7 million in Q4 2025, and -$19.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | -20.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.90 Mn |
| Dec 31, 2025 | -19.74 Mn |
| Sep 30, 2025 | -19.20 Mn |
| Jun 30, 2025 | -19.32 Mn |
| Mar 31, 2025 | -14.67 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Sep 30, 2024 | -12.86 Mn |
| Jun 30, 2024 | -9.58 Mn |
| Mar 31, 2024 | -32.77 Mn |
| Dec 31, 2023 | -7.66 Mn |
| Sep 30, 2023 | -3.75 Mn |
| Jun 30, 2023 | -7.15 Mn |
| Mar 31, 2023 | -8.79 Mn |
| Dec 31, 2022 | -8.86 Mn |
| Sep 30, 2022 | 4.10 Mn |
| Jun 30, 2022 | -11.83 Mn |
| Mar 31, 2022 | -20.85 Mn |
| Dec 31, 2021 | -17.96 Mn |
| Sep 30, 2021 | -16.46 Mn |
| Jun 30, 2021 | -17.13 Mn |